BRII-B(02137) signs intellectual property license and technology transfer agreement with Joincare Pharmaceutical Group Industry.

BRII-B (02137) announced that its wholly-owned subsidiary, Brii Biosciences, Inc. (Teng Sheng Bo Yao Meiguo), has signed a knowledge transfer and technology licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd. (Joincare Pharmaceutical Group Industry). According to the agreement, Joincare Pharmaceutical Group Industry will have exclusive rights to research, develop, and commercialize BRII-693 in mainland China, Hong Kong, Macau, and Taiwan (collectively referred to as Greater China). Under the agreement, Joincare Pharmaceutical Group Industry will be fully responsible for the development, regulatory approval, and commercialization of BRII-693 in the Greater China region. As part of the deal, Teng Sheng Bo Yao Meiguo has received an initial payment and will receive additional milestone payments upon reaching certain development and commercialization milestones, as well as a sales share based on the net sales of BRII-693. Dr. Zhi Hong, Chairman and CEO of the company, stated, "The growing threat of antimicrobial resistance in Greater China underscores the urgent need for new hospital antibiotics. Joincare Pharmaceutical Group Industry has a proven track record in the production and commercialization of hospital antibiotics, making them an ideal partner to accelerate the development and commercialization of BRII-693. This collaboration allows us to provide critical care medications for Chinese patients facing life-threatening infections." Mr. Nanqi Lin, CEO of Joincare Pharmaceutical Group Industry, commented, "Teng Sheng Bo Yao has a long-standing presence in the field of innovative drug research and development, with a strong expertise. The BRII-693 project, supported by Teng Sheng Bo Yao's mature R&D system, demonstrates a high level of professionalism and innovation. The project has shown positive results in disease treatment potential, pharmacological characteristics, and pharmacokinetics, and has the potential to become a Best-in-Class drug, addressing the unmet clinical needs. We are optimistic about the clinical development prospects of BRII-693, and this collaboration further strengthens Joincare Pharmaceutical Group Industry's strategic positioning in the anti-infection pipeline. We look forward to the early launch of this drug and providing patients with more high-quality treatment options."